Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

Inclusion Criteria: * Good health; any underlying chronic illness must be documented to be in stable condition * Highly unlikely to conceive through 6 weeks after administration of the study vaccine Exclusion Criteria: * Prior administration of any pneumococcal vaccine * History of invasive pneumococcal disease (IPD) \[positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture-positive pneumococcal disease * Known hypersensitivity to any vaccine component * Known or suspected impairment of immune function * Received systemic corticosteroids for \>=14 consecutive days and has not completed treatment \<=30 days prior to study entry, or received systemic corticosteroids exceeding physiologic replacement doses within 14 days prior to study vaccination * Coagulation disorder contraindicating intramuscular vaccination * Receives immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation, or autoimmune disease * Received a blood transfusion or blood products, including immunoglobulins within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion. * Participated in another clinical study of an investigational product within 2 months before the beginning of or any time during the duration of the current clinical study * Breast feeding * User of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence